S 0121
Latest Information Update: 21 Aug 1997
Price :
$50 *
At a glance
- Originator Aventis
- Class Antihypertensives; Muscle relaxants
- Mechanism of Action Potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 21 Aug 1997 No-Development-Reported for Hypertension in USA (Unknown route)
- 13 Nov 1996 Preclinical development for Hypertension in USA (Unknown route)
- 07 Dec 1995 Preclinical development for Undefined in USA (Unknown route)